

TUESDAY 13 NOVEMBER 2018

7:15 AM to 8:15 AM

Breakfast Sessions

Looking for money? Try improvement and implementation science

Meeting Room 3

Improvement and implementation science is increasingly recognised as critical to ensure quality of cancer care and timely adoption of best evidence into clinical practice. Research funding bodies require that research proposals consider how research findings will be translated into practice making knowledge of improvement and implementation necessary for both research and practice. This session will outline fundamental concepts of improvement and implementation science and explore how they can be utilised in clinical practice to improve outcomes and increase value and how they can strengthen research applications to make them more competitive.

Chair: Bogda Koczwara**Speakers:** Bogda Koczwara, Christine Paul

The conference acknowledges the sponsorship of

**How to manage challenging family interactions and promote effective family involvement in cancer care: Launching the TRIO Guidelines**

River View Room 4

Family caregivers regularly attend consultations as patients' supporters/advocates and often provide unpaid, personalised care to cancer patients. When informed and empowered, family caregivers can be valuable partners in cancer care. However, research shows that oncology clinicians do not always meaningfully engage with family caregivers. Also, some family members can introduce challenges, such as if they dominate the patient, request private patient information, disagree with the patient's treatment wishes or display anger towards staff. Building a positive working relationship with family caregivers and managing these challenges require confidence and skill.

The TRIO Guidelines for communicating with family caregivers provide clear, specific and evidence-based recommendations for oncology health professionals interacting with a patient's family.

This session will provide an overview of the TRIO Guidelines, and will highlight specific behaviours and phrases that clinicians can use to build a productive relationship with their patients' family caregivers.

Professionally produced short films will be featured, which demonstrate skills from the TRIO Guidelines used in common clinical scenarios.

Attendees will be provided with a hardcopy booklet of the TRIO Guidelines.

Oncology health professionals, researchers and consumers are invited to attend the TRIO Guidelines breakfast launch.

Chair: Christobel Saunders**Speakers:** Ilona Juraskova, Phyllis Butow, Rebekah Laidsaar – Powell

The conference acknowledges the sponsorship of



8:30 AM to 9:00 AM

Opening Ceremony

Chair: Phyllis Butow

Riverside Theatre

Welcome by COSA President

Welcome to Country by local indigenous group

Official opening by The Honourable Kim Beazley AC, Governor of Western Australia

9:00 AM to 10:30 AM

Plenary

(Upper) GI Cancers – The colliding junction

Chair: Eva Segelov

Riverside Theatre

9:00 AM

Dirk ArnoldRefining systemic therapy in GOJ tumours – Can we cure more patients? *abs# 1*

9:20 AM

Mohammed BallalSurgical perspective TBC *abs# 2*

9:40 AM

Theodore HongPre- or Post-operative chemoradiation for GE junction cancer *abs# 3*

10:00 AM

Marian A.E. de van der SchuerenAction against cancer-related malnutrition – An international perspective in the age of obesity *abs# 4***Morning Tea, Poster Viewing and Exhibition (see Poster Listing 1)**

10:30 AM to 11:00 AM

Pavilion 1 (Exhibition Area)

(Presenters to stand next to posters)

11:00 AM to 12:30 PM

Concurrent Symposia

Inherited cancer syndromes

Chair: Nick Pachter

Meeting Room 1 & 2

11:00 AM

Dean FennellGenetics in mesothelioma *abs# 5*

11:20 AM

Marina WallaceManagement of familial adenomatous polyposis (FAP) *abs# 6*

11:40 AM

Hooi EeInherited cancer syndromes: Tailoring surveillance to the individual *abs# 7*

11:55 AM

Mark JenkinsEpidemiology of lynch syndrome *abs# 8*

12:10 PM

Kim HobbsFacilitating family understanding, adjustment and communication when 'it is in the genes' *abs# 9***Up in smoke – medicinal cannabis**

Chair: Judith Lacey

Riverside Theatre

11:00 AM

Justin SinclairCannabis and the endocannabinoid system *abs# 10*

11:20 AM

John SkerrittMedicinal cannabis – Regulation, access and efficacy *abs# 11*

11:40 AM

Jennifer MartinUsing knowledge of clinical pharmacology and therapeutics to guide choice of product and dose in clinical trials *abs# 12*

11:55 AM

Stephen ClarkeCancer pain and cannabis *abs# 13*

12:10 PM

Rob ZielinskiHow are oncology clinic conversations changing with the advent of legalising medical marijuana? *abs# 14*

Protons and other particles: a guide for the non-radiation oncologist

Chair: Yvonne Zissiadis

River View Room 5

- 11:00 AM **Theodore Hong**
Protons in radiation oncology *abs# 15*
- 11:25 AM **Mark Lee**
Upper gastrointestinal cancers challenges and potential benefits in charged particle therapies *abs# 16*
- 11:50 AM **Peter Gorayski**
A Primer on proton therapy for the non-Radiation Oncologist *abs# 17*
- 12:15 PM **Panel Discussion**

Best of the Best Orals – Gastro-intestinal cancers

Chair: David Goldstein

Meeting Room 3

Discussant: Dirk Arnold

- 11:00 AM **Arthur Richardson**
Focusing and sustaining cancer surgical care for high-risk procedures – Oesophagectomies and pancreatectomies in NSW *abs# 18*
- 11:15 AM **David Wyld**
Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland? *abs# 19*
- 11:30 AM **Ashray Gunjur**
A pilot study of patients' preferences for upfront resection versus a 'watch and wait' approach after neoadjuvant long course chemoradiation for locally advanced rectal cancer: What is avoiding surgery worth? *abs# 20*
- 11:45 AM **Sue-Anne McLachlan**
Australian consensus statement on hepatitis B management during immunosuppression for haematological and solid-organ malignancies *abs# 21*
- 12:00 PM **Monica Robotin**
Liver cancer knowledge in Arabic and Assyrian communities in Sydney: Results of a community consultation *abs# 22*
- 12:15 PM **Hui You**
Utilisation of adjuvant chemotherapy for people with stage III colon cancer in NSW *abs# 23*

The conference acknowledges the sponsorship of

**Best of the Best Orals – Supportive care**

Chair: Mei Krishnasamy

River View Room 4

Discussant: Sanchia Aranda

- 11:00 AM **Laura Kirsten**
Development of cancer-specific manualised depression treatment *abs# 24*
- 11:15 AM **Nicole Kiss**
Technology-supported self-guided nutrition and physical activity interventions in adults with cancer: A systematic review *abs# 25*
- 11:30 AM **Samantha Korver**
Personalised supportive care for patients receiving 5-fluorouracil (5-FU): Analysis of multivariate SNP risk prediction for GI toxicity *abs# 26*
- 11:45 AM **Carolyn Mazariego**
Unmet supportive care needs in long-term survivors of prostate cancer: 15-year follow-up of the NSW prostate cancer care and outcomes study *abs# 27*
- 12:00 PM **Kate Secombe**
Pre-treatment *Blautia* abundance regulates chemotherapy-induced gastrointestinal toxicity risk: A pilot study *abs# 28*
- 12:15 PM **Claudia Zecena Morales**
Return to work in survivors of human papillomavirus-associated oropharyngeal cancer: An Australian experience *abs# 29*

The conference acknowledges the sponsorship of



Lunch and Exhibition

12:30 PM to 1:30 PM

Pavilion 1 (Exhibition Area)

COSA Cancer Pharmacists Group Meeting
COSA Nutrition Group Meeting
COSA Survivorship Group Meeting
COSA Regional and Rural Group Meeting
COSA Exercise & Cancer Group Meeting

Meeting Rooms 1 and 2
 Meeting Room 3
 River View Room 4
 River View Room 5
 Riverside Theatre

The conference acknowledges the sponsorship of

**1:30 PM to 3:00 PM****Plenary****Controversies in mesothelioma**

Chair: Anna Nowak

Riverside Theatre

1:30 PM

Sonja KlebeWhy we should biopsy all patients with mesothelioma? *abs# 30*

1:40 PM

Amanda SegalSparing patients a biopsy – Cytological diagnosis of mesothelioma should be enough *abs# 31*

1:50 PM

Sonja Klebe and Amanda Klebe

Cytology vs. biopsy

2:05 PM

John EdwardsSurgery in pleural mesothelioma – A 20-year controversy *abs# 32*

2:30 PM

Lynette DavidThe patient perspective *abs# 33*

2:35 PM

Dean FennellIs immunotherapy a panacea for mesothelioma? *abs# 34***Afternoon Tea, Poster Viewing and Exhibition (see Poster Listing 1)**

3:00 PM to 4:00 PM

Pavilion 1 (Exhibition Area)

(Presenters to stand next to posters)

The conference acknowledges the sponsorship of

**4:00 PM to 5:30 PM****Concurrent Symposia****Precision prevention of colorectal cancer**

Chair: Nicholas Pachter

Riverside Theatre

4:00 PM

Mark JenkinsCan genetic risk profiling aid risk categorization for colorectal cancer? *abs# 35*

4:20 PM

Hooi EeA gastroenterologist's perspective of the implications of risk stratified colorectal cancer screening (including that based on genomic assessment) *abs# 36*

4:40 PM

Jon EmeryImplementation of colorectal cancer risk prediction in primary care *abs# 37*

5:00 PM

Kathleen O'ConnorPolicy implications of risk stratified colorectal cancer screening *abs# 38*

5:20 PM

Panel Discussion at the End

Symptom control in thoracic malignancies

Chair: Rob Zielinski

River View Room 5

- 4:00 PM **Rajesh Thomas**
Management of malignant pleural effusions *abs# 39*
- 4:15 PM **Fraser Brims**
Palliative care in mesothelioma *abs# 40*
- 4:30 PM **Paul Glare**
Thoracic malignancies: Difficult pain management *abs# 41*
- 4:50 PM **John Edwards**
Surgery for palliative symptom control in thoracic malignancy *abs# 42*
- 5:10 PM **Mo Mo Tin**
Palliative radiation therapy in malignant pleural mesothelioma *abs# 43*

The conference acknowledges the sponsorship of

**What's new in liver cancer**

Chair: Chris Karapetis

Meeting Room 1 & 2

- 4:00 PM **Michael Wallace**
Hepatologist's perspective on the management of HCC *abs# 44*
- 4:20 PM **Bryon Jaques**
Surgical management of hepatocellular cancer in patients with liver disease *abs# 45*
- 4:40 PM **Mark Lee**
Stereotactic body radiotherapy for liver tumours – Who should we treat? *abs# 46*
- 4:55 PM **Lara Lipton**
The role of systemic therapy in primary HCC *abs# 47*
- 5:10 PM **Shaun Samuelson**
State of the art and emerging interventional radiology HCC management *abs# 48*

Best of the Best Orals – Basic and translational

Chair: Nikolajs Zeps

Meeting Room 3

Discussant: Clare Scott

- 4:00 PM **Veenoo Agarwal**
Can mammographic breast density predict complete pathological response in patients with locally advanced breast cancer following neoadjuvant chemotherapy? *abs# 49*
- 4:20 PM **Seong Beom Ahn**
Plasma microparticle proteome reveals potential prognostic biomarkers for the colorectal cancer *abs# 50*
- 4:40 PM **Cassandra Nichols**
The ICCon familial cancer database *abs# 52*
- 5:00 PM **Melissa Southey**
Precision breast and prostate cancer risk management: Evidence-based translation of epigenetic testing *abs# 53*

The conference acknowledges the sponsorship of



Best of the Best Orals – Health services

Chair: Michael Cain

River View Room 4

Discussant: Marian A.E. de van der Schueren

- 4:00 PM **Jon Emery**
The RAGE project: A step-wedge implementation of Rapid Access Gastrointestinal Endoscopy (RAGE) services in Melbourne *abs# 54*
- 4:15 PM **Tara Nababan**
'I had to tell my doctor that I had lung cancer': Communication between hospital and community-based lung cancer care *abs# 55*
- 4:30 PM **Jesmin Shafiq**
Radiotherapy utilisation in New South Wales (NSW) for selected cancers: Comparison of actual versus optimal rates and the influencing factors *abs# 56*
- 4:45 PM **Joanne Shaw**
Building Bridges: Addressing the barriers and facilitators to support sustainable implementation of community-based shared care for depression in cancer *abs# 57*
- 5:00 PM **Jane Stewart**
Exploring nutrition knowledge, practice and education needs in regards to cancer malnutrition in the primary care and community sector *abs# 58*
- 5:15 PM **David Weller**
The International Cancer Benchmarking Partnership: Routes to diagnosis for colorectal cancer *abs# 59*

The conference acknowledges the sponsorship of

**COSA Rare Cancers Group Meeting**

5:30 PM to 6:30 PM

Meeting Room 3

Welcome Function

5:30 PM to 7:00 PM

Pavilion 1 (Exhibition Area)

7:00 PM to 10:00 PM

Sponsored Dinner Symposium

River View Room 5

Emerging NGS Biomarkers in Oncology

Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalised way. Sandip Patel, MD, is a board-certified medical oncologist who specialises in cancer immunotherapy and early phase clinical trials involving immunotherapy across all types of cancers. Dr. Patel is focused on developing personalised therapies that stimulate a patient's immune system to attack their specific tumor. He believes in offering these promising immunotherapeutics across all tumor types.

Chair: Tom Berkovits, Director, Market Development**Speaker:** Sandip P. Patel, MD, Medical Oncologist, Assistant Professor of Medicine US San Diego Health

The conference acknowledges the sponsorship of



WEDNESDAY 14 NOVEMBER 2018

7:15 AM to 8:45 AM

Breakfast Sessions

Meet the Professors – Dirk Arnold and John Edwards ‘Surgical resection for metastatic CRC – Truly curative or just chemosparing’

Meeting Room 3

The conference acknowledges the sponsorship of

**Cancer malnutrition is everyone's problem – the multidisciplinary approach**

Riverview Room 4

All members of the multidisciplinary team are encouraged to join us for this informative and interactive breakfast session. Cancer malnutrition is a significant issue for our patients with a substantial impact on quality of life and outcomes. Our speakers will discuss the latest research and strategies for multidisciplinary management of malnutrition and using the case study of the highly successful malnutrition in Victorian cancer services program, how we as clinicians can ensure our issue is heard by government and policy makers.

Chair: Nicole Kiss**Speakers:** Marian A.E. de van der Schueren, Stephen Clarke and TBC from the Victorian Department of Health and Human Services

The conference acknowledges the sponsorship of

**NET – Connecting the last 110 years**

River View Room 5

Content: It is with great pleasure that we invite you all to this year's IPSEN sponsored symposium – ‘N.E.T – Connecting the Last 110 Years’ – from when Siegfried Orberndorfer first coined the term ‘karzinoide’ for what we now refer to as neuroendocrine tumours (NETs). This screening will take you back in time to 1907, on a journey through the last 110 years of NETs history, focusing on scientific discoveries, diagnostic advances and treatment developments, all of which have contributed to optimising patient care. At pivotal points of the film, our expert faculty will offer insight and opinion on the innovations and collaborations that have led to improvements in patient care over the past century.

Join us and take your seats to enjoy learning about how the past can help to shape the future.

The conference acknowledges the sponsorship of

**Mesothelioma and the 3rd wave of exposure**

Meeting Rooms 1 and 2

In 2018, we are still seeing patients diagnosed with mesothelioma. In fact, the numbers continue to remain steady. Asbestos was taken out of building products in 1983 and banned from most work sites in the late 70s. If we have been efficient in eradicating asbestos, then why are we still experiencing disease. We still have end user exposures, asbestos in buildings and products imported containing asbestos. Exposure continues to occur today. The purpose of this presentation is to discuss the legal ramifications of 3rd wave or in situ exposures. We will be addressing the complex legal causation issues that such cases throw up together with imported products.

Chair: TBC**Speaker:** Jonathan Walsh, Principal Lawyer, Maurice Blackburn

The conference acknowledges the sponsorship of



9:00 AM to 10:30 AM

Plenary

Cancer genomics and personalised medicine

Chair: Nick Pavlakis

Riverside Theatre

| | |
|----------|---|
| 9:00 AM | Alistair Forrest The Western Australian cancer single cell initiative <i>abs# 60</i> |
| 9:20 AM | Benhur Amanuel Integrating genetic and genomic testing into the routine pathology workflow <i>abs# 61</i> |
| 9:40 AM | Dean Fennell Genomics directed clinical trials <i>abs# 62</i> |
| 10:00 AM | Clare Scott The NOMINATOR Trial – Panel testing in the Australian Context <i>abs# 63</i> |
| 10:20 AM | Panel Discussion |

Morning Tea, Poster Viewing and Exhibition (see Poster Listing 2)

10:30 AM to 11:00 AM

Pavilion 1 (Exhibition Area)

*(Presenters to stand next to posters)**The conference acknowledges the sponsorship of*

11:00 AM to 12:30 PM

Concurrent Symposia

From malnutrition to obesity: current challenges in optimising for nutrition in people with cancer

Chair: Nicole Kiss

Riverside Theatre

| | |
|----------|---|
| 11:00 AM | Marian A.E. de van der Schueren Nutritional interventions in patients with cancer <i>abs# 64</i> |
| 11:25 AM | Judy Bauer International nutrition audit in foregut tumours (INFORM): An exploration of nutrition care processes in cancer care settings <i>abs# 65</i> |
| 11:50 AM | Erin Laing Nutritional impact of a gastroenteropancreatic neuroendocrine tumour from a patient's perspective <i>abs# 66</i> |
| 12:10 PM | Emily Jeffery Malnutrition and sarcopenia in patients with malignant pleural mesothelioma <i>abs# 67</i> |

Progress on occupational cancer in Australia – let's talk about lungs

Chair: Melissa Ledger

Meeting Rooms 1 and 2

| | |
|----------|--|
| 11:00 AM | Tim Driscoll Exposure and burden of disease related to occupational carcinogens <i>abs# 68</i> |
| 11:15 AM | Ken Takahashi Asbestos-related diseases in the global context <i>abs# 69</i> |
| 11:30 AM | Robert McDonald Regulatory compliance – Why it is not enough to protect the health of workers <i>abs# 70</i> |
| 11:45 AM | Simon Millman Occupational cancer and compensation – The legislative aspects <i>abs# 71</i> |
| 12:00 PM | Arthur William (Bill) Musk Occupational (lung) cancers and compensation <i>abs# 72</i> |
| 12:15 PM | Panel Discussion |

Phase I trials – what's hot

Chair: Michael Millward

River View Room 5

- 11:00 AM **Jayesh Desai**
Development of integrated Phase I trials in a Comprehensive Cancer Centre *abs# 73*
- 11:40 AM **Zelda Herbst**
The Oncology Phase I unit at Linear Clinical Research *abs# 74*
- 11:55 AM **Mihitha Ariyapperuma**
Outcomes of patients going through trials at a Phase 1 clinical trials unit *abs# 75*
- 12:10 PM **Panel Discussion**

Best of the Best Orals – Epidemiology

Chair: Claire Vajdic

River View Room 4

Discussant: John Edwards

- 11:00 AM **Nicola Creighton**
Understanding underuse of surgery for early non-small cell lung cancer – Contribution of enhanced comorbidity ascertainment from population-level hospital and pharmaceutical dispensing data *abs# 76*
- 11:15 AM **Anne Cust**
A risk prediction model for the development of subsequent primary melanoma in a population-based cohort *abs# 77*
- 11:30 AM **Huah Shin Ng**
Patterns of comorbidities in women with breast cancer: A Canadian population-based study *abs# 78*
- 11:45 AM **Julia Steinberg**
Large-scale systematic analysis of relationships between cancer risk factors and their joint association with cancer incidence *abs# 79*
- 12:00 PM **Rebecca Venchiarutti**
Influence of remoteness of residence on timeliness of diagnosis and treatment, and survival of patients with head and neck cancer in New South Wales, Australia *abs# 80*

The conference acknowledges the sponsorship of



Digital distress: how to avoid it when implementing electronic patient monitoring systems

Chair: Haryana Dhillon

Meeting Room 3

- 11:00 AM **Haryana Dhillon**
Introduction
- 11:05 AM **Bogda Koczwara**
Implementation of digital technology in cancer care: What can we learn from published evidence? *abs# 81*
- 11:20 AM **Phyllis Butow**
Adapting distress screening to local settings: how are we doing this? *abs# 82*
- 11:35 AM **Afaf Girgis**
It's a long road to 'business as usual': Where to for the PROMPT-Care eHealth system? *abs# 83*
- 11:50 AM **Joanne Shaw**
'If we build it will they really come': What is needed to implement sustainable e-Health systems *abs# 84*
- 12:05 PM **Panel discussion**

Lunch and Exhibition
12:30 PM to 1:30 PM
COSA AGM

Pavilion 1 (Exhibition Area)
Meeting Room 3

The conference acknowledges the sponsorship of



1:30 PM to 1:50 PM

Tom Reeve Award Presentation and Oration
2018 recipient Professor Grant McArthur

Riverside Theatre

1:50 PM to 3:20 PM

Plenary

MDT panel discussions

Riverside Theatre

This session follows a highly successful format used at previous meetings. It is designed to provide a forum for discussion of the complex issues, which arise in the care of patients with mesothelioma and colorectal cancer. The chairs will present a series of challenging clinical cases and engage members of the multidisciplinary panel in discussion. There will also be opportunities for members of the audience to contribute to the discussion.

Case 1: Early mesothelioma

Co-chairs: Anna Nowak and Melvin Chin

Panel: **Caitlin Broderick** – Nurse**John Edwards** – Thoracic surgeon**Dean Fennell** – Medical oncologist**Gary Lee** – Respiratory physician**Kenneth Lee** – Pathologist**Mo Mo Tin** – Radiation oncologist**Case 2: Management of rectal cancer and concurrent liver mets**

Chair: Tim Clay

Panel: **Dirk Arnold** – Medical oncologist**Mayank Bhandari** – Liver surgeon**Chris Hemmings** – Pathologist**Theodore Hong** – Radiation oncologist**Nicole Newell** – Nurse**Cameron Platell** – Surgeon**Afternoon Tea, Poster Viewing and Exhibition (see Poster Listing 2)**

Pavilion 1 (Exhibition Area)

3:20 PM to 4:00 PM

*(Presenters to stand next to posters)**The conference acknowledges the sponsorship of*

4:00 PM to 5:30 PM

Concurrent Symposia

Stoma management

Chair: Marie Condon

Meeting Room 1 & 2

4:00 PM

Jennifer RyanColorectal surgery and stoma formation *abs# 85*

4:20 PM

Lisa RichardsStoma management, education and troubleshooting *abs# 86*

4:40 PM

Sascha McMeekinNutritional management of stomas *abs# 87*

5:00 PM

Haryana DhillonSex, sleep, survival with a stoma: how people adjust and how we can support them *abs# 88*

5:15 PM

Panel discussion**Medicine matters: 'Getting the dose right'**

Chair: Jim Siderov

Riverside Theatre

4:00 PM

Christine CarringtonUp close and personal. How do we get the dose of cancer therapy right for every patient? *abs# 89*

4:20 PM

Michael PowellAnticancer therapy in the older patient – Getting the dose right *abs# 90*

- 4:40 PM **Chris Lomma**
Sarcopenia significance in drug dosing – Can it be embraced in the clinic? *abs# 91*
- 4:55 PM **Michael Cain**
LFT derangement and cancer chemotherapy – Guidelines and a black art *abs# 92*
- 5:10 PM **Daniel McKavanagh**
Electronic prescribing impact on chemotherapy errors – The good / the bad / the ugly *abs# 93*

Lung cancer screening and prevention in Australia

Co-chairs: Fraser Brims and
Annette McWilliams

River View Room 4

- 4:00 PM **Annette McWilliams**
Lung cancer screening in Australia – What's new and what's recommended *abs# 94*
- 4:15 PM **Stephen Melsom**
Detection of early lung cancer – A radiology perspective *abs# 95*
- 4:30 PM **David Manners**
Patient decision aids – Improving understanding and avoiding decisional conflict *abs# 96*
- 4:45 PM **Emma Dean**
Managing smoking in lung cancer patients: It's time to start the conversation *abs# 97*
- 5:05 PM **Fraser Brims**
Follow-up and early detection after lung cancer treatment – What should we be doing? *abs# 98*
- 5:20 PM **Panel discussion**
The conference acknowledges the sponsorship of



Best of the Best Orals – Clinical research (featuring Mesothelioma)

Chair: Kenneth Lee

Meeting Room 3

Discussant: Dean Fennell

- 4:00 PM **Nazim Abbas**
'Real World' application of Nivolumab and the impact of performance status on outcomes of in patients with advanced non-small cell lung cancer (NSCLC) *abs# 99*
- 4:15 PM **Yuen Cheng**
Circular RNAs as novel biomarkers for detection of malignant pleural mesothelioma *abs# 100*
- 4:30 PM **Edward Harris**
Low-dose CT screen-detected malignant and non-malignant findings in a Western Australian asbestos-exposed cohort: Results from the first five years of screening *abs# 101*
- 4:45 PM **Peey-Sei Kok**
DREAM – A Phase 2 trial of DuRvalumab with first line chemotherapy in Mesothelioma: Final result *abs# 102*
- 5:00 PM **Wei-Sen Lam**
A Phase II clinical trial of the single agent oral FGF receptor inhibitor AZD4547 as Second of Third Line Therapy in Malignant Pleural Mesothelioma: Final results of the FRAME study *abs# 103*
- 5:15 PM **Graham Pitson**
Impact of altered radiotherapy treatment fractionation on acute skin toxicity in breast cancer *abs# 104*

The conference acknowledges the sponsorship of



COSA Psycho-oncology Group Meeting

5:30 PM to 6:30 PM

Meeting Room 3

COSA Spring Soiree Evening Function

6:30 PM to 11:00 PM

Summer Gardens

THURSDAY 15 NOVEMBER 2018

7:45 AM to 8:45 AM

Breakfast Sessions

Best of the Best Poster discussion A – Translational and Clinical research

Chair: Anne Cust

Meeting Room 3

Discussant: Michael Powell

- 7:45 AM **Nicole Bartley**
Advanced cancer patient perspectives on consenting to molecular tumour profiling: A qualitative study
abs# 302
- 7:50 AM **Wee Loong Chin**
A bioinformatics approach to biomarker validation using publically available RNAseq data from
immunotherapy trials *abs# 304*
- 7:55 AM **Frederic Hollande**
Optical barcoding highlights novel characteristics of treatment resistant cells in metastatic colorectal
cancer *abs# 308*
- 8:00 AM **Graham Rivers**
Psychotropic combined with Chemotherapeutics Drug Interaction Tool: An essential time-saving
resource for clinicians *abs# 356*
- 8:05 AM **Peter Smith**
Complementary and alternative medicine use by patients receiving curative-intent chemotherapy
abs# 357
- 8:10 AM **Tom van Hagen**
Avelumab treatment of Australian patients with metastatic Merkel cell carcinoma (mMCC): experience
from an expanded access program (EAP) *abs# 365*
- 8:15 AM **Emily Jeffery**
Potential role for a novel body composition analysis technique in patients with malignant pleural
mesothelioma *abs# 372*

The conference acknowledges the sponsorship of



Best of the Best Poster discussion B – Optimal care pathways and Health services research

Chair: Nicole Kiss

River View Room 4

Discussant: Patsy Yates

- 7:45 AM **Jon Emery**
Upskilling the primary care workforce in cancer survivorship *abs# 378*
- 7:50 AM **Jenny Post**
An optimal care pathway for Aboriginal and Torres Strait Islander people – Closing the gap on culturally
safe cancer care *abs# 387*
- 7:55 AM **Jennifer Chynoweth**
Improving outcomes for Aboriginal and Torres Strait Islander people with cancer through an Optimal
Care Pathway *abs# 193*
- 8:00 AM **Kimberley Durber**
Measuring financial toxicity in Australian Cancer Patients – Validation of the comprehensive score for
financial toxicity (COST) *abs# 200*
- 8:05 AM **Sashie Howpage**
Assessing the impact of outreach Oncology clinics in remote New South Wales *abs# 206*
- 8:10 AM **Abhijit Pal**
Repetitive blood testing in medical oncology ward inpatients – A retrospective 6-week audit of
incidence, clinical yield and cost in a large Sydney tertiary referral hospital *abs# 225*
- 8:15 AM **Jesmin Shafiq**
Estimating the cost benefit of radiotherapy for 5-year local control and overall survival *abs# 229*

8:20 AM

Haitham TuffahaCan we prospectively assess the value for money of oncology clinical trials? *abs# 234*

The conference acknowledges the sponsorship of


2018 update on CINV (Chemotherapy Induced Nausea & Vomiting) and TARGIN® tablets – Utilisation in the treatment of chronic cancer pain

River View Room 5

Speakers: Prof Dorothy Keefe and A/Prof Michael Franco

This breakfast session will discuss the latest antiemetic guideline recommendations and treatment options in chemotherapy-induced nausea and vomiting (CINV). This will include the use of NK-1 receptor antagonists or 'triple therapy' in patients receiving carboplatin or oxaliplatin – containing chemotherapy agents, emerging evidence in dexamethasone-sparing antiemetic regimens and data on the NEPA combination as well as olanzapine in CINV control and prevention. This session will explore the data to support the use of TARGIN® tablets in the treatment of chronic cancer pain in daily doses up to 160/80 mg, examine the importance of the ongoing assessment of hepatic function and outline how to manage safe opioid rotation from TARGIN® tablets in light of deteriorating liver function.

The conference acknowledges the sponsorship of



9:00 AM to 10:30 AM

Concurrent Symposia

Psychiatric issues of patients with cancer

Chair: Phyllis Butow

River View Room 4

9:00 AM

Jane TurnerSupporting the patient with personality vulnerability during cancer care *abs# 105*

9:20 AM

Lisa Miller

Case presentation: A multi-disciplinary systemic approach to caring for the complex patient with serious mental illness during chemotherapy (including tips for safely managing psychotropics and steroid therapy)

Panel members: Michael Cain, Oncology Pharmacist, Sir Charles Gairdner Hospital, WA

Dr Andrew Hart, Palliative Care Physician, Kalamunda Palliative Care Service, WA

James Penhale, Clinical Psychologist, WA Psycho-oncology Service, WA

Karen Proctor, Clinical Nurse Consultant, Palliative Care, Sir Charles Gairdner Hospital, WA

Dan Rigg, Senior Social Worker, Sir Charles Gairdner Hospital, WA *abs# 106*

9:55 AM

Panel Discussion: Managing complex delirium in cancer patients *abs# 107*

Chair: Lisa Miller

Panel members: Prof Meera Agar, Professor of Palliative Medicine, University of Technology Sydney, NSW

Dr Felicity Hawkins, Palliative Medicine Physician and Geriatrician, Sir Charles Gairdner Hospital, WA

Dr Cathy Mason, Senior Staff Specialist Psychiatrist in Oncology, Crown Princess Mary Cancer Centre, Westmead, NSW

Karen Proctor, Palliative Care Clinical Nurse Consultant, Sir Charles Gairdner Hospital, WA

Prof Jane Turner, Department of Psychiatry, University of Queensland, QLD

Life goes on – financial health during cancer care

Chair: David Joske

Meeting Room 1 & 2

9:00 AM

Christine PaulImpact of financial costs of cancer on patients – The Australian experience *abs# 108*

9:30 AM

Sanchia ArandaPatient out-of-pocket expenses *abs# 109*

9:50 AM

Kimberley Durber

Measuring financial toxicity in Australian cancer patients – Validation of the comprehensive Score for financial Toxicity (COST) *abs# 110*

10:05 AM

Piyush GroverMedicines access programs to cancer medicines in Australia and New Zealand: An exploratory study *abs# 111*

10:15 AM

Panel Discussion

GEPNET: Changing paradigms in neuroendocrine tumours

Chair: David Ransom

Meeting Room 3

- 9:00 AM **Chris Hemmings**
The WHO (2017) classification: What's changed? *abs# 112*
- 9:30 AM **Nick Pavlakis**
Evolving treatment modalities and current clinical trials in NETs *abs# 113*
- 10:00 AM **Ben Lawrence**
New discoveries in tumor biology that might matter in the clinic *abs# 114*

Improving outcomes for cancer of unknown primary

Chair: Linda Mileshkin

River View Room 5

- 9:00 AM **Linda Mileshkin**
Introduction
- 9:10 AM **Tharani Sivakumaran**
Clinical impact of the CUPGuide and Comprehensive Cancer Panel in the SUPER national prospective study: Experience of the first 2 years *abs# 115*
- 9:25 AM **Richard Tothill**
New horizons in translational research of cancer of unknown primary *abs# 116*
- 9:40 AM **Penelope Schofield**
Poor understanding of the diagnosis predicts psychological morbidity in Cancer of unknown primary patients *abs# 117*
- 9:55 AM **Cindy Bryant**
Experiencing cancer of unknown primary as a carer: Perspectives from the SUPER study consumer *abs# 118*
- 10:10 AM **Linda Mileshkin**
Development of the optimal care pathway for cancer of unknown primary *abs# 119*

Morning Tea and Exhibition

10:30 AM to 11:15 AM

Pavilion 1 (Exhibition Area)

11:15 AM to 12:45 PM**Plenary****Exercise & cancer**

Chair: Nigel Spry

Riverside Theatre

- 11:15 AM **Scott Fisher**
Mice, Meso and Exercise *abs# 120*
- 11:30 AM **Carolyn McIntyre**
Exercise for patients with mesothelioma *abs# 121*
- 11:45 AM **Janette Vardy**
Challenges in physical activity for colorectal cancer survivors *abs# 122*
- 12:15 PM **Prue Cormie**
Implementing exercise in cancer care *abs# 123*

COSA Presidential Lecture

12:45 PM to 1:30 PM

Riverside Theatre

Chair: Phyllis Butow

Speaker:

Tim Hammond
The politics of cancer

Conference Closes

1:30 PM

Riverside Theatre

POSTER LISTING 1

Conference Theme: Gastrointestinal Cancers**Sushma Agrawal**

Prognostic factors affecting Overall Survival (OS) in Gallbladder Cancer (GBC) on Cisplatin-Gemcitabine (CG) *abs# 150*

Fiona Bellamy

Intra-abdominal desmoid tumour – An unusual case of the acute abdomen *abs# 151*

Chau Bui

Evaluation of a simplified Tumour-Node-Metastasis staging system in a population-based cancer registry *abs# 152*

Wanyuan Cui

Oral capecitabine versus intravenous 5-Fluorouracil and Leucovorin in Stage II and III Colorectal Cancer: The Bendigo Experience 2007 – 2017 *abs# 153*

Kirsten Duggan

Colon Cancer Stage and Treatment Patterns in relation to culturally and linguistically diverse (CALD) Status, in South West Sydney Local Health District (SWSLHD) *abs# 154*

Kirsten Duggan

Rectal Cancer Stage and Treatment Patterns in relation to patient's culturally and linguistically diverse (CALD) Status, in South West Sydney Local Health District (SWSLHD) *abs# 155*

Nathan Dunn

The safety and efficacy of colorectal cancer surgery in Queensland *abs# 156*

David Goldstein

Can health service utilisation by gastrointestinal cancer patients be assessed using data from a biobank? *abs# 157*

Lauren Hanna

The association between body composition and stage of pancreatic cancer at diagnosis *abs# 158*

Justin Harvey

Statistics on gastrointestinal cancers diagnosed in Australia *abs# 159*

Kristin Hsu

Role of screening in geriatric population at risk of developing cancer treatment related toxicities *abs# 161*

Andrew Laycock

Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) – The other microsatellite instability *abs# 162*

Mwila Kabwe

Presenting symptoms among oesophagogastric cancer patients at a regional Loddon Mallee hospital *abs# 163*

Mwila Kabwe

Mapping the optimal Care Pathway (OCP) for people with oesophagogastric cancer at two regional Victorian hospitals *abs# 164*

Lisi Elizabeth Lim

Mortality in early stage colorectal cancer: A comparative analysis between a regional and metropolitan centre in Victoria *abs# 165*

Sarah Maloney

Changes in colorectal cancer (CRC) presentation over a 10 year period (2005. – .2016) in South Western Sydney Local Health District (SWSLHD): Results from a clinicopathological database *abs# 167*

Christina Mullany

Impact of rural and remoteness on overall survival in Australian patients with Stage I to III colorectal cancer *abs# 168*

Kathleen O'Connor

WA Histology Data Collection Project: Findings from Rounds 1 – 6 *abs# 169*

Carol Parker

Using a rapid improvement event to identify solutions to improve timelines of the oesophagogastric cancer journey through a regional Victorian hospital *abs# 170*

Andrew Parsonson

Retrospective analysis of clinical characteristics and outcomes for anal cancer patients in the South West Sydney Local Health District (SWSLHD) between 2010 – 2017 *abs# 171*

Sarenya Pathmanandavel

Cancer stem cell markers in metastatic gastroesophageal adenocarcinoma *abs# 172*

Sathira Perera

Benchmarking the optimum surgical utilization rate for common gastrointestinal tumours in Australia *abs# 173*

David Ransom

Western Australian survival data for gastrointestinal cancers 1995 to 2014 with comparative data for 5 other high-income countries. On behalf of the International Cancer Benchmarking Partnership (ICBP) *abs# 174*

Kirsty Rowan

Evaluation of nutrition outcomes and clinician compliance of an evidence based nutrition care pathway for upper GI cancer patients undergoing radical chemoradiation therapy *abs# 175*

Arvind Sahu

Capecitabine and temozolomide (CAPTEM) for intermediate to high grade metastatic neuroendocrine tumours (NET): A single centre experience *abs# 176*

Mohsen Shafiei

Patterns of care and survival outcomes of younger versus older adults with stage I to IV rectal cancer at Concord Repatriation General Hospital *abs# 177*

Mary Theophilus

When is 'enough' data really too much? Data capture in the CIC Cancer Project *abs# 178*

Inga Tinton

Gastrointestinal Cancers – Targeted therapy use is more prevalent in patients with left-side colon cancer in Australia *abs# 179*

Victoria White

Patterns of care for patients with oesophageal cancer in Victoria: Data prior to implementation of Optimal Care Pathways *abs# 180*

Desmond Yip

Outcomes of patients with metastatic gastro-oesophageal cancer who received palliative systemic therapy in the Australian Capital Territory (ACT) *abs# 181*

Louise Young

A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma (uHCC) *abs# 182*

Health Services**Eva Arneric**

Participating in an International Stereotactic Radiotherapy Patient Registry *abs# 183*

Kirsty-Anne Baxter

Standardizing multidisciplinary approach for patients who are prescribed oral chemotherapy in our cancer centre *abs# 186*

Sarah Blaschke

Victorian end-of-life care professionals' attitudes toward voluntary assisted dying *abs# 187*

Geoffrey Bryant

Implementing a highly accessible model of screening and assessment in geriatric oncology: Our experience *abs# 188*

Geoffrey Bryant

Colorectal cancer patient reported outcomes: putting theory into practice *abs# 189*

Phyllis Butow

Unmasking Anxiety: A qualitative investigation of health professionals' perspectives of mask-anxiety in head and neck cancer *abs# 190*

Grace Chazan

Referral practices and patient outcomes in regional Victoria Oncology Care *abs# 191*

Xue Zhen Choo

To evaluate the impact of a pharmacy driven protocol that converts standard rituximab infusions to subcutaneous for eligible patients *abs# 192*

Jennifer Chynoweth

Shared follow-up care for women with low-risk endometrial cancer *abs# 194*

Jennifer Chynoweth

Position Statement on genetic testing for women diagnosed with ovarian cancer *abs# 195*

Greg Cook

Beyond the data, what is the role of those affected by cancer in reimbursement decisions? *abs# 196*

Barbara Daveson

The Lung Cancer Framework: Optimising lung cancer service delivery *abs# 197*

Jodi Dumbrell

Formative-process evaluation of the dietetic service and model of care provided to day therapy at Peter MacCallum Cancer Centre *abs# 199*

Kate Fennell

Improving outcomes for rural cancer survivors in Australia: New research questions from an International Churchill Fellowship *abs# 201*

Gabriel Gabriel

The effect of new radiotherapy departments on the accessibility of cancer patients to the nearest radiotherapy facilities in NSW *abs# 202*

Chun Loo Gan

Survey on patterns of travel for patients attending chemotherapy day units in Monash Health – A local experience *abs# 203*

Phyllis Butow

Digging into context: a qualitative study of staff experiences during pre-implementation of the Australian Clinical Pathway for the Screening, Assessment and Management of Anxiety and Depression in Adult Cancer Patients *abs# 204*

Sean Hill

Piperacillin/Tazobactam use for non-neutropenic fever in a Tertiary Hospital Medical Oncology Department *abs# 205*

Susannah Jacob

The effect of changes in indications for chemotherapy on the optimal chemotherapy utilisation rate in early breast cancer *abs# 207*

Elizabeth Kernutt

Introduction of a standardised on-treatment radiation mucositis pain management protocol in a head and Neck Cancer Oncology Unit *abs# 208*

Nicole Kiss

Patient experience of a multidisciplinary optimisation clinic for cancer patients with complex needs *abs# 209*

Judith Lacey

Enhanced supportive care program: Incorporating integrative oncology in a comprehensive cancer service *abs# 210*

Wei-Sen Lam

An Innovative Nursing Model to Support Country People Receiving Oral Treatment for Cancer *abs# 211*

Belinda Lambros

Description of the rationale and core domains of an antimicrobial stewardship in cancer specialist nursing role *abs# 212*

Geraldine Largey

The Victorian Lung Cancer Service Redesign Program: Learnings intended to inform development of future redesign projects *abs# 213*

Geraldine Largey

The Victorian Lung Cancer Service Redesign Project: How technology enhanced understanding of project impact *abs# 214*

Gabrielle Lie

Implementation of a validated chemotherapy prediction tool in a busy oncology clinic *abs# 215*

Caroline Lum

Implementation and results of the Victorian Cancer Patient Experience Survey (VCPES) at Monash Health *abs# 216*

Angelita Martini

The impact of parental cancer on preadolescent children (0 – 11 years) in Western Australia: A longitudinal population study *abs# 217*

Jeanie Misko

Safety from bag to vein: Infusion management in a tertiary oncology centre *abs# 218*

Raghav Murali-Ganesh

From smartphone to electronic health record (EHR): An innovative implementation of patient-reported outcomes and patient-generated health data in routine cancer care *abs# 219*

Genni Newnham

The growing problem of cancer in Victorian prisoners: A description of cancer diagnoses, demographics, risk factors and barriers to optimal care *abs# 220*

Jade Newton

Cancer costs experienced by Western Australian cancer patients *abs# 221*

Huah Shin Ng

Patterns of health service utilisation among the Australian population with cancer compared to the general population *abs# 222*

Tate Jacobson

Potential length of stay reduction with outpatient management of low risk febrile neutropenia *abs# 223*

Shaun O'Connor

Improving chemotherapy quality and safety – VicTAG chemotherapy audit toolkit *abs# 224*

Jenny Post

Using the Optimal care pathways to measure the impact of variation in care: Developing a framework to drive a research agenda *abs# 226*

Evelien Rosens

Building Clinical Trial Capability in Nascent Clinical Groups: Strategies and lessons learned *abs# 227*

Catherine Schembri

An audit of unplanned hospitalisations in oncology patients undergoing outpatient chemotherapy *abs# 228*

Michelle Barrett

Building and connecting a cancer workforce through collective impact *abs# 230*

Neli Slavova-Azmanova

How communication between cancer patients and their specialists affect the quality and cost of cancer care *abs# 231*

Adam Stoneley

Delivering cancer clinical trials to as many people as possible, as close to home as possible: Icon's Remote Access to Clinical Trials (ReACT) Program *abs# 232*

Parth Thaker

Rural Cancer Awareness and Early Detection Initiative (RCAEDI) *abs# 233*

Craig Underhill

Establishing Leadership in Regional Oncology within the Victorian Comprehensive Cancer Centre *abs# 235*

Emily Watters

Is there a role for GPs in patient care following a lung cancer diagnosis? An assessment of the communication between hospital physicians and primary care providers *abs# 237*

Jane Weber

Assessing oesophagogastric cancer care in Victoria against the optimal care pathway *abs# 238*

Robert Woolas

Early detection of endometrial cancer following transvaginal ultrasound scan (TVS) performed in one centre of the United Kingdom collaborative trial of ovarian cancer screening (UKCTOCS): Long term survival data of screen detected cases *abs# 239*

Aylin Yahya

Piloting a web-based electronic Patient Reported Outcomes (ePRO) Portal for patients receiving CyberKnife radiotherapy treatment *abs# 240*

Supportive Care**Elise Alexander**

Hearing patients' children: A systematic review of the current interventions available for children living with parental cancer *abs# 241*

Marliese Alexander

Cardiac monitoring practices in breast cancer patients receiving anthracyclines and HER-2 targeted agents – A single centre retrospective study *abs# 242*

Kelcey Bland

Effect of exercise training on chemotherapy completion rates in individuals with cancer: A systematic review *abs# 243*

Michael Cain

Successful etoposide phosphate desensitisation as management for an uncommon and poorly characterised hypersensitivity reaction – Case report and review of literature *abs# 244*

Prue Cormie

EX-MED Cancer: A Best Practice Exercise Medicine Program for People with Cancer *abs# 245*

Stevie Cosentino

Time to antibiotic administration in suspected febrile neutropenic patients presenting to Royal Darwin Hospital Emergency Department *abs# 246*

Keith Cox

Online learning improves nurse and pharmacist confidence in managing chemotherapy-induced nausea and vomiting (CINV) *abs# 247*

Wanyuan Cui

Dose modification for haematological toxicity: A survey of Australian Medical Oncologists *abs# 248*

Eunice Dai

The incidence and severity of breakthrough nausea and vomiting with palonosetron and dexamethasone requiring addition of NK1-receptor antagonists (NK1RA) in subsequent cycles in three highly or high-risk moderately emetogenic chemotherapy (HEC and high MEC) regimens *abs# 249*

Julia Dixon-Douglas

Venous thromboembolism in patients with glioblastoma multiforme at the Royal Hobart Hospital *abs# 250*

Kate Fennell

Rural Cancer Stories: The power of online, video-based, peer-directed information and support *abs# 251*

Derya Iren Akbiyik

A psychosocial support program from Mamak Municipality in Turkey for breast cancer patients; psychodrama group therapy and collaboration with the patients for screening and early diagnosis in the community *abs# 252*

Rachael Keast

A systematic review of inventions to improve carer involvement in medical consultations and decision making *abs# 253*

Rachael Keast

A web review of online advice for carers on how to engage in medical consultations and decisions *abs# 254*

Laura Kirsten

Accelerating access to psychosocial services: Rapid Psychosocial Assessment Clinic *abs# 255*

Chi Hao La

An expanded role oncology pharmacist adds value to symptom and urgent review clinics *abs# 256*

Judith Lacey

Non-pharmacological approach to cancer-related pain *abs# 257*

Rebekah Laidsaar-Powell

Psychosocial experiences of cancer survivors: A qualitative metareview *abs# 258*

Wei-Sen Lam

Expansion of TelePalliative Care in the home in regional Western Australia *abs# 259*

Dan Luo

Resilience in adult cancer care: A review and concept analysis *abs# 260*

Aditya Manna

Difficulties in providing palliative care in rural India (West Bengal) – Experience of an NGO *abs# 261*

Michael Marthick

Feasibility and acceptability of an interactive web-portal for oncology patient physical activity and symptom tracking *abs# 262*

Fiona McRae

Development of Counterpart Navigator information app for women with a gynaecological cancer *abs# 263*

Annie Miller

Podcasts – A sound way for patients and carers to engage with cancer information *abs# 264*

Christine Muttiah

A retrospective review of toxicity and tolerability of weekly paclitaxel in early stage breast cancer (ESBC): A single centre experience *abs# 265*

Matthew Perich

Nursing context of exercise promotion for persons with haematological cancer *abs# 266*

Robert Wojnar

The use of propofol in an acute hospice setting for continuous palliative sedation *abs# 267*

Karen Taylor

Qualitative results of a Phase II pilot randomised controlled trial of a lymphoma nurse-led survivorship model of care *abs# 268*

Darshit Thaker

Retrospective study to understand the timeline and outcome of Aged Care Assessment of inpatients in the Palliative Care Unit at Redcliffe Hospital *abs# 269*

Megumi Uchida

Are existing delirium assessment tools appropriate for terminal delirium assessment among cancer patients? *abs# 270*

Jane Weber

Investigating practices relating to supportive care screening in Victorian cancer services *abs# 271*

Betty Zhang

Decision-making regarding cessation of endocrine therapies at the end of life *abs# 272*

Eva Zopf

Effects of supervised aerobic exercise on quality of life and fatigue in colorectal cancer patients undergoing adjuvant chemotherapy *abs# 273*

POSTER LISTING 2

Basic and Translational Research

Abidali Mohamedali

Decreased cancer cell-surface urokinase plasminogen activator receptor (uPAR) negates several hallmarks of cancer *abs# 300*

Nicole Bartley

Young cancer patient perspectives on undertaking whole genome sequencing: A qualitative study *abs# 301*

Khobe Chandran

Epithelial-to-mesenchymal transition as a Robust Biomarker and a novel strategy to enhance response to immune checkpoint blockade and targeted therapy in patients with metastatic renal cell carcinoma *abs# 303*

Bin-Bin Cong

A new fluorescence-targeted tracer for sentinel lymph node biopsy *abs# 305*

Danielle Gessler

The decision-making process in adolescents and young adults with cancer and their families: A systematic review *abs# 306*

Mwila Kabwe

Development of a Quality Framework for Cancer Multidisciplinary Team meetings in Victoria *abs# 307*

Zhen Hou

Radiomic analysis using Contrast-Enhanced CT: Predict treatment response to pulsed low-dose rate radiotherapy in gastric carcinoma with peritoneal cavity metastasis *abs# 309*

Angela Ives

Measuring what's important to our patients: The Continuous Improvement in Care - Cancer (CIC Cancer) Project *abs# 310*

Matt Johnson

Translational Medicine - The uptake of pan-cancer panel testing in Australia *abs# 311*

Shaun Liow

CD4/CD8 ratio correlates with lymph node involvement in patients with oral cavity squamous cell carcinoma *abs# 312*

Mwila Kabwe

Optimising sub-regional nurse-led oncology services supported by outreach through action research planning *abs# 313*

Sue Merritt

Applying implementation science principles to Optimal Cancer Care within primary health at scale *abs# 314*

Tim Miller

Validation of the prognostic and predictive value of the cancer stem-like cell marker SOX2 in colorectal cancer *abs# 315*

Bella Nguyen

Tumour-derived extracellular vesicles (EV) - A real time functional assessment of tumour activity in patients with head and neck cancer (HNC) *abs# 316*

Bella Nguyen

Prognostic utility of CDX2 and PD-L1 in Rectal Cancer *abs# 317*

Anna K Nowak

Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors (AUTO-CHECK study) *abs# 318*

Elizabeth Thomas

Accurate measurement of tumor mutation burden through tumor-only sequencing using a 500-Gene Panel *abs# 319*

Yu-Chi Wang

The effect of radiotherapy combined with iron oxide-based Nanovehicle and Photosensitizer in Osteosarcoma *abs# 320*

Fanxin Zeng

RIPK1 binds MCU to mediate induction of mitochondrial Ca²⁺ uptake and promote colorectal oncogenesis *abs# 321*

Clinical Research**Afaf Abed**

The cost effectiveness of primary versus secondary prophylaxis with pegylated G-CSF to prevent hospitalization due to febrile neutropenia amongst early breast cancer patients *abs# 322*

Tamim Adam

Definitive chemoradiotherapy for stage II - III non-small cell lung cancer: Patient outcomes in South Western Sydney Local Health District *abs# 323*

Anas Alawawdeh

Cisplatin and Vinorelbine with radiotherapy for local advanced non-small cell lung cancer - How good is it? *abs# 324*

Belinda Bahari

Conducting early-phase oncology clinical trials: Experience of a dedicated clinical trial unit *abs# 325*

Tim Ball

Adherence to antibiotic guidelines in the management of febrile neutropenia *abs# 326*

Amy Body

PD1 inhibitors and endocrine dysfunction: Patterns and outcomes *abs# 327*

Emma Carson

'Is the bar high enough' A review of pre-clinical and clinical evidence used for Phase 3 trials in castrate resistant prostate carcinoma *abs# 328*

Rossa King

Cardiotoxicity in advanced HER2 positive breast cancer in real world Australian patients receiving HER2-targeted therapy in the first-line setting *abs# 329*

Philip Craven

Attitudes to Inferior Vena Cava Filters (IVCFs) among Medical Oncologists, Haematologists and Respiratory Physicians *abs# 330*

James Fletcher

Review of the integrated exercise physiology (EP) clinic at a tertiary cancer centre: Experience from the Adem Crosby Centre, Sunshine Coast University Hospital (SCUH) *abs# 331*

Tim Humphries

Clinical implementation of personalised medicine for 6 high priority WA cancers *abs# 332*

Fiona F. Jonker

Remaining financially viable in the clinical trials industry requires the skill set of Harry Houdini *abs# 333*

Rachael M. Keast

Exploring head and neck cancer patients' experiences with radiation therapy immobilisation masks: A qualitative study *abs# 334*

Wei-Sen Lam

Prediction of recurrence and survival using PET SUV Max in patients with resected non-small cell lung cancer *abs# 335*

Angela Maerten

Afatinib for patients with EGFR mutation-positive (EGFRm+) NSCLC: Activity in patients with baseline brain metastases and impact on the rate of central nervous system (CNS) progression or spread *abs# 336*

Angela Maerten

Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: experience in 'real-world' clinical practice *abs# 337*

Angela Maerten

Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced Non-Small Cell Lung Cancer (NSCLC) in a real-world setting *abs# 338*

Hikomichi Matsuoka

Multicentre, randomised, double-blind, placebo-controlled trial of additive duloxetine for cancer-related neuropathic pain refractory to opioids and gabapentinoids *abs# 339*

Peter McGuire

Standardising the measurement of cancer patient experience in Queensland: A feasibility study *abs# 340*

Peter McGuire

Utilising non-admitted code sets for an Outpatient cancer patient experience survey *abs# 341*

Michelle McMullen

Dexamethasone and obesity-related complications amongst patients with Glioblastoma; A retrospective review of a single tertiary center *abs# 342*

Marinella Messina

Phase 1 study of NOX66 in combination with Carboplatin in patients with end stage solid tumours *abs# 343*

Lisa Miller

A case of neuropsychiatric and neurological sequelae of severe radionecrosis of the corpus callosum following cyber-knife radiotherapy in a young female patient treated for metastatic melanoma *abs# 344*

Cristina A Moldovan

Management of brain metastases in patients with HER2 positive breast cancer – A real world Australian experience *abs# 345*

Jan Mumford

GastroIntestinal cancer consumers in research partnership *abs# 346*

Sharon Nahm

Factors associated with fear of cancer recurrence in breast and colorectal cancer survivors *abs# 347*

Jennifer Nicol

Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma *abs# 348*

Jane Phillips

A Phase II cluster randomised controlled trial of a multi-component non-pharmacological intervention to prevent delirium for in-patients with advanced cancer (The PRESERVE pilot study) *abs# 349*

Graham Pitson

Non-small cell lung cancer treated with radical radiotherapy or chemoradiation: A retrospective review at a regional cancer centre *abs# 350*

Graham Pitson

Bladder cancer treatment patterns and outcomes *abs# 351*

Shane Qin

Improving clinical pathways of oncology patients in the gippsland region *abs# 352*

Parameswar R Rachumalla

Is serum CA15-3 useful for assessing disease progression during systemic therapy in patients with metastatic breast cancer (MBC)? *abs# 353*

Parameswar R Rachumalla

Retrospective analysis of clinical characteristics and outcomes for patients enrolled in oncology Phase 0 and Phase 1 clinical trials at Liverpool Cancer Therapy Centre *abs# 354*

Ajay Raghunath

Real-world experience of nivolumab monotherapy in advanced non-small cell lung cancer (NSCLC): Retrospective analysis from a large tertiary centre *abs# 355*

Megan Smith-Uffen

Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients *abs# 358*

Laura Tam

Exploring the feasibility of rechallenging immunotherapy in lung and melanoma patients following a grade 3–4 immunotherapy-related adverse event *abs# 359*

Marianna Theodoulou

An overview of radiation necrosis in patients with brain metastases who received stereotactic radiosurgery with or without systemic treatment including immunotherapy at Sir Charles Gairdner Hospital *abs# 360*

Craig Underhill

Implementation of an Investigator Initiated Teletrial *abs# 361*

Barbara van der Meij

Early signs of impaired gut function in patients with advanced cancer undergoing chemotherapy *abs# 362*

Barbara van der Meij

Baseline clinical but not metabolic characteristics of cancer subjects dropping out of a clinical trial during chemotherapy are different from non-dropout subjects *abs# 363*

Tom van Hagen

Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma (mMCC) progressed on chemotherapy *abs# 364*

Louise Young

A Phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck *abs# 366*

Louise Young

Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results *abs# 367*

Louise Young

Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results *abs# 368*

Louise Young

Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma *abs# 369*

Louise Young

Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer *abs# 370*

Conference Theme: Mesothelioma**Yuen Yee Cheng**

Combination of microRNAs provide a synergistic effect on growth inhibition on MPM cells *abs# 371*

Graham Pitson

Population-based analysis of pleural mesothelioma patterns of care and outcomes in regional Victoria *abs# 373*

Education**Manuela Boyle**

Adult cancer survivors' health literacy and their management of chronic symptoms secondary to oncologic treatments in Australia *abs# 374*

Caitlin Broderick

A survey of the Western Australian Cancer Nurse Coordinators: A comparison of attitudes and knowledge about smoking cessation interventions and nicotine dependence pre- and post-online training *abs# 375*

Caroline Bulsara

Caring for the carer: Empowering carers through educational workshop participation *abs# 376*

Sathana Dushyanthen

Adding colour to cancer: The art, science and education trifecta *abs# 377*

Georgia Halkett

Exploring the carer's experience of looking after a person diagnosed with primary brain cancer: an exploration of carers' experiences during nurse-led phone interviews for the intervention 'Care-IS' *abs# 379*

Georgia Halkett

What support are carers requiring over time during nurse-led support provided as part of the Care-IS study?: Preliminary results *abs# 380*

Georgia Halkett

The complexity of diagnosing sarcoma in a timely manner *abs# 381*

Aisling Kelly

Ten years of collaborative learning and fostered networking for NSW Oncology and Haematology Pharmacists *abs# 382*

Tiffany Foo

Thymic Hyperplasia following treatment with checkpoint inhibitors in a patient with stage IV Melanoma *abs# 383*

Sue Merritt

A new way to talk about cancer – Trialing a cancer pop up shop in Melbourne's West *abs# 384*

Natasha Moloczij

Building a cancer nursing research hub using formative evaluation design *abs# 385*

Courtney Oar

A virtual cancer pharmacy education program for pharmacists and technicians across an international, multi-site organisation *abs# 386*

Liz Simkiss

A collaborative approach to improving men's health *abs# 388*

Peter Smith

The use of a brochure to enable CAM-with-chemotherapy patient education *abs# 389*

Joan Thomas

Oncology/Haematology 24 hour triage rapid assessment and access tool kit – Aussie Style *abs# 390*

Epidemiology**Michael Allen**

Are we overtreating Queensland cancer patients near end-of-life? *abs# 391*

Ciara Daly

A single centre experience of Pneumocystis jirovecii pneumonia (PJP) in patients with solid organ malignancy *abs# 392*

Pardeep Dhanda

QOOL-Dash: Converting data to accessible information for real-time monitoring of outcomes for patients reviewed at MDT *abs# 393*

Nathan Dunn

Quality of care and quality of life for Queensland colorectal cancer patients *abs# 394*

Ashley M Hopkins

Early on-therapy arthralgia predicts improved response and survival in advanced melanoma patients treated with vemurafenib and vemurafenib plus cobimetinib: A pooled analysis of clinical trial data *abs# 395*

Tate Jacobson

Febrile Neutropenia in a regional setting; Epidemiology and microbiology findings *abs# 396*

Kim Kennedy

The rising incidence of neuroendocrine tumours – An epidemiological study of incidence and mortality of Neuroendocrine Neoplasms in Western Australia *abs# 397*

Mwila Kabwe

Characteristics at presentation among prostate cancer patients diagnosed in the Loddon Mallee region of Victoria *abs# 398*

Claire Lee-Koo

The Australian Mesothelioma Registry *abs# 399*

Marina van Leeuwen

Cardiovascular toxicity of targeted therapies for cancer: an overview of systematic reviews *abs# 400*

Service Provision

Mark Flower

An audit of the time and completeness of diagnosis in primary advanced lung cancer at a regional public cancer centre without onsite bronchoscopy *abs# 401*

Curtis Forbes

Implementation of an integrated exercise physiology (EP) service within a tertiary cancer centre: Experience from the Adem Crosby Centre, Sunshine Coast University Hospital (SCUH) *abs# 402*

Haakan Jakobsson

Improving the rate of documented patient consent for systemic therapy at a tertiary cancer care centre: A quality improvement project from the Sunshine Coast University Hospital *abs# 403*

Anne King

Audit of patient and carer initiated telephone calls to a neuro-oncology cancer coordinator service *abs# 404*

Katherine Lane

Patient and caregiver satisfaction with Cancer Council 13 11 20 Information and Support Services: An outstanding report-card on the provision of empathetic, person-centred supportive care *abs# 405*

Margaret Patterson

Implementation of a centralised Charm governance framework across a national pharmacy organisation *abs# 406*

Neil Reynolds

26-week results of the oncology pharmacist contribution to a pilot counselling service for oncology patients starting oral anticancer drugs (OADs) *abs# 407*

Danielle Roscoe

Using Patient Reported Outcome Measures to inform cancer survivorship care and improve outcomes in a regional Victorian setting *abs# 408*

Adam Stoneley

Access to Phase 1 Clinical Trials Closer to Home-Integrating Phase 1 trials in to a busy private practice *abs# 409*

Julie Symons

Outcomes of a new cancer rehabilitation and survivorship service in a rural hospital *abs# 410*

Julia Todd

Using the optimal care pathway for people with lung cancer to conduct a gap analysis of patient care coordination requirements *abs# 411*

Trials in Progress

Emma Carson

The WinPro Study: A window of opportunity study of endocrine therapy with and without prometrym in post-menopausal women with early stage hormone receptor-positive breast cancer *abs# 412*

Evelien Rosens

ALT-TRACC: A registry-based randomised trial investigating alternating oxaliplatin and irinotecan doublets in treatment-naïve metastatic colorectal cancer *abs# 413*

Jeffrey Goh

ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer *abs# 414*

Merryn Hall

NUTMEG: A randomised Phase II study of Nivolumab and Temozolomide (TMZ) vs TMZ alone in elderly patients with newly diagnosed Glioblastoma (GBM): Trial in progress *abs# 415*

Aisling Kelly

Getting the dose right – Controversies in renal and hepatic dysfunction *abs# 416*

Chee Khoon Lee

A Phase 2 trial of durvalumab and tremelimumab with chemotherapy in metastatic EGFR mutant non-small cell lung cancer following progression on EGFR tyrosine kinase inhibitors (ILLUMINATE) *abs# 417*

Thomas McFarlane

A pilot Study of a Nurse and Pharmacist Led OTN (Ontario Telemedicine Network) based clinic for management of prostate cancer patients on oral therapy *abs# 418*

Sue-Anne McLachlan

BR31: A Phase 3, double blind, placebo controlled, randomized trial of adjuvant durvalumab in completely resected non-small cell lung cancer *abs# 419*

Antony Mersiades

Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV) *abs# 420*

Antony Mersiades

Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate) *abs# 421*

Linda Mileshkin

PEARL: A randomised phase 3 trial of early referral to palliative care (PC) for patients with advanced thoracic malignancies *abs# 422*

Paul Mitchell

A randomised open-label phase 2 trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after concurrent chemo-radiotherapy (STIMULI) *abs# 423*

Paul Mitchell

NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy (SABR) in advanced non-small cell lung cancer (NSCLC), progressing after first or second line chemotherapy *abs# 424*

Elizabeth Paton

'It takes a village' – Investigator-Initiated Clinical Trials in Melanoma and Non-Melanoma Skin Cancers (NMSCs) *abs# 425*

Christine Paul

Developing strategic and collaborative research partnerships: case-studies demonstrating strategies to identify additional research questions and priorities – The START trial experience *abs# 426*

Isabell Vocks

NOX66 in combination with Palliative Radiotherapy in patients with mCRPC – A Phase 1 safety and dose finding study *abs# 427*